Beachbody Company, Inc. — Form 8-K Summary
Business Context and Reporting Period
The Company reported material financing and warrant amendments effective April 5, 2024. The filing was signed and furnished with a related press release on April 8, 2024. The transaction relates to Beachbody, LLC’s senior secured term loan facility originally funded at $50.0 million and administered by Blue Torch Finance, LLC.
Key Financial and Capital Structure Developments
- The Company amended its financing agreement through Amendment No. 5.
- The minimum revenue covenant was revised to $100.0 million for each fiscal quarter ending after April 5, 2024 through December 31, 2024.
- The minimum revenue covenant increases to $110.0 million for each fiscal quarter thereafter through December 31, 2025.
- The minimum liquidity covenant was revised to $18.0 million at all times from April 5, 2024 through maturity of the credit facility.
- Beachbody, LLC made a $4.0 million partial prepayment of term loan principal, plus accrued interest and a $120,000 prepayment premium.
- The filing does not provide the remaining outstanding principal balance, interest rate, maturity date, or current liquidity balance.
- The Company amended and restated warrants covering 97,482 shares of Class A common stock. The exercise price was reduced from $20.50 to $9.16 per share.
Material Changes Versus the Prior Arrangement
- The financing amendment changed the minimum revenue and minimum liquidity requirements.
- The Company reduced term loan principal by $4.0 million but incurred a $120,000 prepayment premium, in addition to accrued interest.
- The warrant exercise price was substantially reduced, increasing the potential economic value of the warrants and potential dilution if exercised.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide operating guidance, earnings guidance, or a broader business outlook. The revised covenants indicate that compliance will depend on achieving at least $100.0 million of quarterly revenue through 2024, at least $110.0 million of quarterly revenue during the specified 2025 periods, and maintaining at least $18.0 million of liquidity.
Failure to satisfy the revised covenants could create financing-related risks, including potential default or enforcement actions; the filing does not describe applicable cure rights, waivers, or lender remedies. The $4.0 million debt prepayment and $120,000 premium are unusual cash uses associated with the amendment. The lower warrant exercise price may increase the likelihood of exercise and potential dilution to existing shareholders.
Important Facts for Investors to Verify
- Review Exhibit 10.1 for the amended covenant definitions, testing dates, cure provisions, maturity date, interest terms, collateral, and default remedies.
- Confirm the remaining term loan balance and the Company’s liquidity after the $4.0 million prepayment and related costs.
- Assess whether the Company is currently meeting the $18.0 million minimum liquidity covenant and the applicable revenue covenant.
- Review Exhibit 10.2 for warrant terms, adjustment provisions, expiration dates, and the potential dilution from 97,482 warrant shares.
- Evaluate the impact of the revised covenants and debt service obligations on future operating flexibility and financing needs.